Methods and systems of using exosomes for determining phenotypes
View Patent ↗Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.
1. A method of detecting an exosome population in a biological sample, comprising determining the presence or levels of a combination of different biomarkers of said exosome population, wherein said combination of different biomarkers comprises:
i. CD9 protein, CD63 protein, CD81 protein, or a combination thereof;
ii. one or more cell-specific protein biomarker, wherein said one or more cell-specific protein biomarker comprises PCSA; and
iii. one or more protein biomarker that is indicative of a cancer.
2. The method of claim 1 , wherein the exosome population is isolated from a bodily fluid from a subject.
3. The method of claim 2 , wherein said bodily fluid is peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, pus, sebum, vomit, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, or blastocyl cavity fluid.
4. The method of claim 1 , wherein said exosome population comprises vesicles having a diameter of about 10 nm to about 800 nm.
5. The method of claim 1 , wherein said exosome population comprises vesicles having a diameter of about 30 nm to about 200 nm.
6. The method of claim 1 , wherein said exosome population is isolated from said biological sample with size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity selection, microfluidic separation or a combination thereof.
7. The method of claim 1 , wherein the cancer is prostate cancer.
8. The method of claim 1 , wherein said determining comprises measuring an expression level, presence, absence, mutation, truncation, insertion, modification, sequence variation or molecular association of said proteins from said isolated exosome population.
9. The method of claim 2 , wherein said bodily fluid is blood, urine, serum or plasma.
10. The method of claim 1 , further comprising determining an amount of exosomes, a temporal evaluation of a variation in exosome half-life, a temporal evaluation of circulating exosome half-life, a temporal evaluation of exosome metabolic half-life, or determining exosome activity.
11. The method of claim 1 , wherein said one or more cell-specific protein biomarker further comprises PSMA.
12. The method of claim 1 , wherein said determining comprises use of one or more binding agent that binds to at least one of said biomarkers.
13. The method of claim 12 , wherein said one or more binding agent comprises an antigen, DNA molecule, RNA molecule, antibody, antibody fragment, aptamer, peptoid, zDNA, peptide nucleic acid (PNA), locked nucleic acids (LNA), lectin, peptide, dendrimer or chemical compound.
14. The method of claim 1 , wherein said one or more protein biomarker further comprises B7H3 protein and/or EpCam protein.
15. The method of claim 14 , wherein said one or more cell-specific protein biomarker further comprises PSMA.
16. The method of claim 7 , wherein said combination of different biomarkers further comprises miR-141 RNA biomarker.
17. The method of claim 7 , wherein said combination of different biomarkers further comprises TMPRSS2-ERG RNA biomarker.
18. The method of claim 14 , wherein said combination of different biomarkers further comprises miR-141 RNA and/or TMPRSS2-ERG RNA biomarker.
19. The method of claims 16 , 17 or 18 , wherein said RNA biomarker is assessed by quantitative PCR, nucleic acid sequencing, hybridization assay or a combination thereof.
20. The method of claim 6 , wherein the affinity selection comprises contacting said exosomes with a binding agent that is specific for a protein biomarker selected from the group consisting of CD9 protein, CD63 protein, CD81 protein, a cell-specific biomarker, a biomarker that is indicative of a cancer, and a combination thereof.
21. The method of claim 1 , further comprising determining a presence or level of one or more microRNA in said exosome population.
22. The method of claim 1 , wherein said one or more of CD9 protein, CD63 protein and CD81 protein comprises CD9 protein.
23. The method of claim 1 , wherein said exosome population comprises a heterogeneous exosome population.
24. A method of detecting prostate cancer in a patient comprising: detecting the levels of PCSA protein and one or more of CD9, CD63 and CD81 protein in isolated exosomes obtained from said patient, wherein elevated levels of said PCSA protein and one or more of CD9, CD63 and CD81 proteins in said isolated exosomes obtained from said patient as compared to levels of PCSA protein and one or more of CD9, CD63 and CD81 proteins in isolated exosomes obtained from a subject that does not have prostate cancer indicates that said patient has prostate cancer.
25. The method of claim 24 , wherein said exosomes are isolated from said patient with size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity selection, microfluidic separation or a combination thereof.
26. The method of claim 25 , wherein the affinity selection comprises contacting said exosomes with a binding agent that is specific for a protein biomarker selected from the group consisting of PCSA protein, CD9 protein, CD63 protein, CD81 protein, and a combination thereof.
27. The method of claim 26 , further comprising determining a presence or level of at least one microRNA in said isolated exosomes.
28. The method of claim 24 , wherein said one or more of CD9, CD63 and CD81 protein comprises CD9 protein.